Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$238.75 USD

238.75
1,334,422

-5.37 (-2.20%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus

QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.

Tirthankar Chakraborty headshot

4 Top Stocks to Invest in for Astounding Earnings Growth

Invest in stocks such as BellRing Brands (BRBR), ResMed (RMD), NVIDIA (NVDA) and Transdigm Group (TDG) for solid earnings growth.

QIAGEN (QGEN) to Enhance Forensics With New Partnership

QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.

Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised

Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.

Nalak Das headshot

U.S. Consumer Sentiment Plummets in May: 5 Safe Stock Picks

We have narrowed our search to five defensive stocks with strong potential for the rest of 2024. These are: ES, ATO, MKC, TSN, RMD.

Teleflex (TFX) Expands Vascular Access Portfolio With New Launch

Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.

AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.

Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand

Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y

Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.

STERIS (STE) Q4 Earnings Match Estimates, Margins Contract

STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.

Zacks.com featured highlights include ResMed, Booz Allen Hamilton and Kontoor Brands

ResMed, Booz Allen Hamilton and Kontoor Brands have been highlighted in this Screen of The Week article.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

3 GARP Stocks to Scoop up for Maximum Returns

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.

Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View

Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.

Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall

Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.

Integra's (IART) Q1 Earnings Match Estimates, Margins Down

Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.

Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View

Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.